1. Introduction
Babesia bovis and Babesia bigemina are the primary causative agents of bovine babesiosis, an economically impactful disease affecting cattle worldwide [1,2,3,4]. While B. bovis has been extensively studied due to its association with cerebral injury, high mortality rates, and significant economic losses, B. bigemina is typically linked to milder acute hemolytic disease, but it can still be highly pathogenic. It is widely distributed and transmitted transovarically by a broad range of Rhipicephalus ticks [5].
Calves exhibit a natural resistance to B. bigemina; however, the disease can be acute in older or immunocompromised animals. Infection with B. bigemina typically manifests more benignly, but severe consequences can arise due to hemolytic anemia, with mortality rates reaching up to 50% without treatment. Additionally, after acute signs resolve, cattle can survive as carriers, suffering from recurrent infections or dying from secondary complications, ultimately impacting animal production [6].
Treatment of B. bigemina with imidocarb (ID) can effectively cure the infection, but it leaves the animal susceptible to reinfection. For this reason, reduced drug dosage levels have sometimes been recommended [7]. However, under field conditions, the use of drugs at subtherapeutic low concentrations, whether prophylactically or in chemoimmunization programs, increases the risk of resistance emergence [8,9,10]. Additionally, imidocarb is associated with residue issues and is not widely available, including in the USA and Europe [7].
Buparvaquone (BPQ) has shown promise in treating Babesia bovis and B. bigemina, as well as other apicomplexan parasites [11,12,13,14,15,16,17,18,19,20,21]. BPQ selectively inhibits the Qo quinone-binding site of the parasite’s mitochondrial cytochrome b electron transport system, leading to its lethal effect [16,22,23,24].
ELQ-316 is another new drug that proved effective in in vitro treatment of Theileria spp. and Babesia spp. parasites. ELQ-316 is an endochin-like quinolone compound (ELQ). ELQ-316 selectively inhibits the Qi quinone-binding site of the parasite’s mitochondrial cytochrome bc1 complex electron transport system and has shown high efficacy against Plasmodium falciparum, Babesia microti, and Toxoplasma gondii. Different ELQ compounds demonstrated a strong antimalarial effect both in vitro and in vivo, along with parasite selectivity, chemical and metabolic stability, desirable pharmacokinetics, and low toxicity to mammalian cells [25].
Effective treatment of babesiosis is crucial for maintaining the health and productivity of livestock. The lack of approved drugs in many countries for controlling babesiosis, and the emergence of drug resistance in Babesia species underscores the need for new treatments. BPQ and ELQ-316 may enhance treatment options, providing effective and safe alternatives, as previously demonstrated [26].
It is well established that there are differences in the susceptibility to antiprotozoal drugs between larger Babesia species (e.g., B. bigemina) and smaller species (such as B. bovis) [1,2]. This indicates that the effects of drugs may not be the same for B. bovis and B. bigemina, and therefore, drugs should be tested independently of data obtained previously from B. bovis. The aim of the present study is to evaluate the efficacy of ID, BPQ, ELQ-316, as well as the combinations of BPQ + ELQ-316 and ID + ELQ-316, in inhibiting the replication of B. bigemina in vitro.
2. Results
2.1. Comparative Inhibitory Effects of BPQ, ID and ELQ-316 and the Combinations ELQ-316 + BPQ and ELQ-316 + ID Against B. bigemina In Vitro Replication
The median and rate survival kinetics of in vitro B. bigemina cultures over 96 h of incubation in the presence of various concentrations (nM) of BPQ, ID, ELQ-316, and the combinations ELQ-316 + BPQ and ELQ-316 + ID, starting at 2% PPE, are shown in Table 1 and Figure 1. At 25 nM, the survival rate observed was comparable for all drugs and drug combinations. At 75 nM, a significant difference was only observed between ID and both drug combinations (BPQ + ELQ-316 and ID + ELQ-316). At 150 nM, significant differences were observed between both ELQ-316 combinations and the three drugs tested individually. A similar pattern was observed at 300 nM, except for ELQ-316, which did not differ (p > 0.05) from the other drugs and combinations tested. At 600 and 1200 nM, all drugs effectively killed B. bigemina.
2.2. Drug Potency
The mean and 95% confidence intervals of IC50% and IC99% values were calculated to compare the potency of the drugs on the growth of in vitro B. bigemina cultures. Results are presented in Table 2. The combination of ELQ-316 + ID demonstrated the lowest IC50%, indicating higher potency in killing B. bigemina. However, it required seven times the IC50% dose (IC99%/IC50%) to achieve 0% survival. The combination of BPQ + ELQ-316 exhibited the second greatest potency. Surprisingly, the concentration required to achieve 0% survival was very close to the IC50%. The potencies of BPQ and ELQ-316 were similar, and the concentration of drugs required to kill completely was between 3 and 3.5 times the IC50%. ID demonstrated the lowest potency, which was similar to that of its combination with ELQ-316; it also required 7 times the IC50% to eliminate the parasites completely.
2.3. Time and Drug Concentration Required to Reach 0% Survival After Treatment
The survival of Babesia bigemina in in vitro cultures after drug treatments of varying durations and doses for each drug and combination is presented in Table 3.
Parasites treated with BPQ at 1200 nM became non-viable after 48 h, while those treated at doses ranging from 300 nM to 1200 nM showed no survival after 72 h. Cultures treated with drug concentrations above 75 nM maintained this trend, reaching 0% survival after 96 h. A similar pattern was observed in cultures treated with ELQ-316.
The combination of BPQ + ELQ-316 demonstrated a superior effect, achieving 0% survival more rapidly. No parasites were detected after 48 h of treatment with BPQ + ELQ-316 at 1200 nM, after 72 h at doses ranging from 300 nM to 1200 nM, and after 96 h at doses ranging from 75 nM to 1200 nM.
In cultures treated with ID + ELQ-316, no parasites were detected after 72 h at concentrations of 600 nM and 1200 nM, and after 96 h at concentrations ranging from 150 nM to 1200 nM. Additionally, after 24 h of incubation in media without ID + ELQ-316, cultures previously treated with concentrations ranging from 75 nM to 1200 nM showed no surviving parasites.
3. Discussion
New, safe, and effective chemotherapies are urgently needed for the global control of bovine babesiosis. Combination drug strategies have proven significantly more effective in eliminating parasites and, importantly, reducing the risk of developing drug resistance compared to single-drug therapies [27].
In this study, we compared the drugs BPQ and ELQ-316, which appear to exert synergistic effects by targeting two distinct sites (Qo and Qi, respectively) in the parasite’s mitochondrial cytochrome bc1 complex. Both combinations tested (ELQ-316 + BPQ and ELQ-316 + ID) demonstrated nearly 100% efficacy in killing B. bigemina at 150 nM over 96 h of treatment. Similar results were observed for ELQ-316 and BPQ monotherapies at the same concentration. Notably, the combination of BPQ + ELQ-316 was the fastest to achieve 0% survival, reaching this endpoint at 96 h with 75 nM and at 48 h with 1200 nM.
The IC50 values for the combinations of BPQ + ELQ-316, BPQ and ELQ-316 were similar. Our calculated IC50 values for ELQ-316 were significantly higher than those reported for B. bigemina and other related apicomplexans in previous studies [28]. For instance, ELQ-316 demonstrated IC50 values of 7.97 nM for Besnoitia besnoiti and 0.66 and 0.35 nM for Toxoplasma gondii tachyzoites [25,29]
Significant differences were observed between BPQ and ID, consistent with findings from previous studies on B. bovis reported by Cardillo, Lacy, et al. (2024) at 1% PPE and 2% PPE [12,30]. Importantly, a significant difference was also observed between the IC50 values of BPQ + ELQ-316, ELQ-316, and BPQ, with the BPQ + ELQ-316 combination demonstrating the highest potency against B. bovis [30].
Regarding the time to achieve 0% survival, the combination of ELQ-316 + BPQ was significantly faster and more effective at lower concentrations compared to the ELQ-316 + ID combination. The ELQ-316 + BPQ combination reached 0% survival at 48 h with 1200 nM and at 72 h with concentrations as low as 300 nM. In contrast, the ELQ-316 + ID combination required 600 nM to achieve 0% survival within the same 72 h timeframe.
In this study, we found that B. bigemina (IC50%: 27.25 nM) was more sensitive to BPQ than B. bovis (IC50: 50.01 nM and 77.06 nM), as reported in our previous work with cultures started at 1% and 2% PPE, respectively [12,30]. This finding contrasts with those of Nugrara et al. (2019), who reported significantly higher drug potency for both parasites, indicating that B. bovis was much more sensitive than B. bigemina (IC50: 135 ± 41 nM and 488 ± 30 nM, respectively). Nugrara’s study utilized starting cultures at 1% PPE and measured parasitemia after 96 h of treatment with a fluorescence-based method using SBYR Green 1 stain [20].
Conversely, a significant difference in parasite survival was observed with the combination of ELQ-316 + ID at 25 nM compared to the other drugs (p < 0.05), which may explain the low IC50 of 9.25 nM (95% CI: 8.67–9.89) for this combination. This represents a substantial improvement in potency compared to each drug individually (ID IC50: 61.49 nM [95% CI: 59.54–63.46]; ELQ-316 IC50: 48.10 nM [95% CI: 42.76–58.83]), suggesting a notable synergistic effect when both drugs are used together. Interestingly, the low IC50 obtained with the combination of ELQ-316 + ID is comparable to that reported by Rizk et al. (2023) for the combination of Diaminazene aceturate (DA) + ID against B. bigemina [31]. The authors demonstrated a synergistic effect of both drugs, with a combination index value (CI) of 0.76, indicating synergy (CI < 0.9) based on the Chou–Talalay method (Chou, 2006). It can be speculated that both drugs may possess complementary mechanisms of action to kill or inhibit the growth of Babesia, a possibility that may also apply to the combination of ELQ-316 + ID.
In this study, ID required a higher concentration to achieve near 0% survival within the same evaluation period (96 h) than the other drugs, with effective results observed at concentrations above 300 nM. While B. bigemina remains more sensitive to ID than B. bovis [12], a significant improvement in drug potency was observed with the combination of ELQ-316. Although the mechanism of action of ID is not well understood [32], as suggested by Silva et al. (2020), the potential presence of a resistant subpopulation may have significantly influenced survival rates when combined with ELQ-316, thereby impacting overall results. Interestingly, the doses and concentrations of each drug required to achieve 0% survival (IC99%) were similar, in proportion, to those observed by Cardillo et al. (2024b) against B. bovis. Among these, ID combined with ELQ-316 and ID alone required the highest doses—almost seven times the IC50—to completely eliminate the parasites in vitro in our study. In the study by Cardillo et al. (2024b), nearly four times the IC50% was required to achieve the same results. This suggests that ELQ-316 may have an additive effect when used with ID, facilitating faster elimination of susceptible parasites. However, a more resistant population that requires higher doses to achieve 0% survival, especially ID, may exist.
Importantly, since ELQ-316 is safer than ID, it could provide a promising option for reducing the therapeutic doses of ID required, thereby minimizing toxic side effects in animals and decreasing residues retained in edible tissues. This combination approach enhances efficacy and aligns with the growing need for safer and more effective treatments in livestock management.
Similar to our previous report about B. bovis [12], a residual effect against parasites was observed after treatment with all drugs and combinations tested. This suggests a persistent effect, likely related to the extent of the impairment or metabolic changes, which depend on the concentration of each drug used. We observed a dose and time-dependence survival effect which align with previous studies on B. bovis using endochin-like quinolones, tulathromycin drugs [28,33], BPQ [12], and artemisinin [34]. Silva et al. (2020) reported that B. bovis, B. caballi, and T. equi were unable to grow in in vitro cultures in the presence of ELQ-316, regardless of their initial percentage of parasitemia (p < 0.05). However, they observed that adding another endochin-like quinolone (ELQ-300) to B. bigemina cultures at an initial parasitemia of 2% did not lead to a rapid decrease in parasitemia, in contrast to the results seen when the initial parasitemia was set at 0.2%. The same effect was observed with ELQ-316 against B. caballi. The authors speculated that this could be due to the presence of pre-existing resistant parasite subpopulations of B. bigemina and B. caballi, capable of surviving the initial drug-inhibitory treatment with ELQ-300 and ELQ-316. It was recently shown that genetic alterations in the Qi binding site of the cytochrome bc1 complex (Cytb) of B. microti is associated with resistance to ELQ-316, suggesting that this cytochrome gene may be as a potential target for the ELQ drugs [35]. This finding supports the idea that combining chemotherapeutics can offer significant advantages, including enhanced effectiveness, reduction in dosage (which may lead to fewer toxic side effects), and lower likelihood of resistance or/and recrudescence. Drugs that produce synergistic effects and inhibit distinct pathways, can also help to prevent anti-drug resistance development [26].
The therapeutic efficacy of in vitro drug screening assays against Babesia spp. is influenced by various factors, including species, strain, and size of the screening parasites, the culture conditions (such as the medium used, percentage of parasitemia [PPE], hematocrit, and the presence or absence of serum), and the methods used to calculate PPE [36,37]. These variables can significantly impact the calculated IC50 values of the tested drugs across different studies [38,39]. There is a critical need for consensus on standardized international methods to improve comparability and reproducibility of results. This would facilitate more accurate comparisons of drug efficacy and enhance our understanding of therapeutic potential across different Babesia species and treatments.
Overall, the ability of all drugs tested to inhibit B. bigemina growth in time and dose concentration was superior to the previous study on B. bovis. At concentrations of 600 nM and above, all drugs were 100% effective in killing B. bigemina. These findings reinforce the notion that large Babesia species (like B. bigemina) are more susceptible to antiprotozoal drugs than smaller species (such as B. bovis). However, no single treatment guarantees a radical cure [1,2]. Differences in size and metabolism between small and large Babesia spp., may lead to variations in drug target and biochemical mode of action [40].
This study focused on the asexual cycle within the definitive host, and therefore, we were unable to directly observe the effects of the treatment on the stages that occur in the tick. Our experimental design was limited to the asexual stages within the erythrocytes, so we cannot determine whether the drug affects other stages outside the host. As for the parasite staging, all observed stages were trophozoites of the Texas strain, which have been maintained in long-term laboratory cultures.
4. Materials and Methods
4.1. Chemical Reagents
Buparvaquone (98% pure) was obtained from Combi-Blocks, Inc. (San Diego, CA, USA). ID (VETRANAL™, Supelco® Buchs, Switzerland) was used as a positive control for the in vitro inhibition assays of B. bigemina, using the same protocol described for BPQ below. The purity of ID was determined to be >98% by proton nuclear magnetic resonance spectroscopy and high-performance liquid chromatography (HPLC), as indicated in the certificate of analysis.
ELQ-316 was synthesized using methods previously described by Nilsen et al. (2014) and identified by proton nuclear magnetic resonance (1H NMR), with a purity of ≥95% confirmed by reversed-phase high-performance liquid chromatography (RP-HPLC) [41].
BPQ, ELQ-316, and ID were diluted in 100% dimethyl sulfoxide (DMSO) to prepare stock solutions, which were stored at room temperature until use. Working solutions were freshly prepared in a parasite culture medium on each test day, just before being added to the parasite cultures.
4.2. Parasites Culture
Babesia bigemina (Puerto Rico Strain: Goff et al. 1998) were grown in long-term microaerophilic stationary-phase cultures at 37 °C in an atmospheric condition of 5% CO2, 5% O2, and 90% N2, as previously described [42]. B. bigemina were cultured in 96 well-culture plates, in 190 μL per well of PL culture media (100 mL = pH 7.2; 29 mL F-12K Nutrient Mixture + L-glutamine (Life Technologies, Carlsbad, California, USA), 29 mL Stable Cell IMDM (Sigma Aldrich, St. Louis, MO, USA), 2 mL 0.5 M TAPSO (Sigma Aldrich, St. Louis, MO, USA, 0.5 mL Antibiotic Antimycotic solution 100× (Sigma Aldrich, St. Louis, MO, USA), 1 mM calcium chloride (Sigma Aldrich, St. Louis, MO, USA), 100 μL Antioxidant Supplement 1000× Sigma Aldrich, 1 mL Insulin-Transferrin-Selenium-Ethanolamine 100× (Sigma Aldrich, St. Louis, MO, USA), 1 mL 50% Glucose (Teknova, Hollister, CA, USA), 500 μL L-glutamine 200 mM (GIBCO, Grand Island, NY, USA), and 40% bovine serum. The cultures were maintained in 5% cells volume of erythrocytes.
4.3. In Vitro Growth of Initial Inhibitory Assay
The in vitro inhibitory efficacy of BPQ, ELQ-316, and ID was evaluated against the growth of B. bigemina, after starting at a percentage of parasitized erythrocytes (PPE) of 2%. The parasitemia level was selected based on previously validated protocols to ensure the presence of a sufficient number of parasites for meaningful drug efficacy testing, while also avoiding excessively high parasitemia that could affect the consistency of the results. The chosen range is between 0.5% and 2%. B. bigemina were cultured in media containing various final concentrations (25, 75, 150, 300, 600, and 1200 nM) of BPQ, ELQ-316, ID, and the combinations of BPQ + ELQ-316 and ID + ELQ-316, diluted in 100% DMSO. Cultures with DMSO (1 μL) and without drug compounds served as positive controls for parasite growth, while additional wells containing uninfected bovine RBCs were used as negative controls.
Parasite cultures were replenished daily with fresh culture media (190 μL/well) containing the respective drug concentrations. The experiments were conducted in triplicate for each concentration and control over 96 h (4 days). PPE was monitored daily by counting parasites in Hema 3 Stat Pack (Fisher Scientific, Pittsburgh, PA, USA) stained thin blood smears (GBS). Before the daily media change, 190 μL of supernatant was removed from each well, and the remaining RBC layer at the bottom was suspended. A 1 μL sample was taken from each well to prepare a thin smear, and the number of infected red blood cells was counted by visually examining 5000 erythrocytes on each slide. Morphological characteristics were also observed. Drug responsiveness of the parasites was measured as the percentage of parasitemia after every 24 h exposure to drug concentrations, up to the 96 h mark.
4.4. Viability After Treatment
At 96 h after the initial treatment, fresh media without drugs were added to all culture wells, along with 5 μL of fresh RBCs. This drug-free medium was replaced daily for the next five days to assess whether the cultures remained viable and could continue growing without the drug. Both quantitative and qualitative parasitemia levels were determined through a microscopic examination of Hema 3 Stat Pack (Fisher Scientific) stained thin blood smears.
4.5. Statistical Analysis
Values of parasitemia were counted daily, and the percentage of survival was calculated, and media comparisons between all tested drugs were performed using the Mann–Whitney test or Kruskall–Wallis test.
The doses of a drug that produced 50% inhibition (IC50%) relative to the control population and the maximal inhibitory concentration (IC99%) were determined for BPQ, ELQ-316, ID, and the combinations, at drug concentrations ranging from 25 to 1200 nM, in 24 h, 48 h, 72 h, and 96 h post-incubation. Total inhibitory concentrations (IC99%) were determined as the drug doses required to reduce parasite growth to the same level observed in non-infected erythrocytes (approximately 0.1%). The survival curves were compared using a log-rank (Mantel–Cox) test. The statistical significance was set at <0.05. GraphPad Prism ver. 7 software for Windows (Graphpad Software Inc., San Diego, CA, USA) was used for the statistical analysis.
5. Conclusions
The findings reinforce the efficacy of the tested drugs in inhibiting B. bigemina parasites in vitro and highlight the promising potential of drug combinations as alternative control strategies. While in vitro efficacy can serve as a reliable predictor of therapeutic potential in vivo, drug screening assays often lack host-related variables tied to pharmacokinetic and pharmacodynamic factors, as well as interactions at non-target sites [43]. Therefore, the therapeutic activity of these potent candidates must be validated in target animal species, bovines.
Variations in parasite species, strains, or culture conditions during in vitro drug screening, along with differing methods for counting parasitemia, can explain the diverse pharmacological interactions observed with drug combinations in various studies. Further research is needed to clarify these differences and deepen our understanding of drug efficacy, the interplay between drug mechanisms of action, and the potential mechanisms of parasite resistance.
The combination therapy involving ELQ-316 with ID or BPQ significantly reduced parasitemia of B. bigemina more effectively than the full-dose monotherapies. Therefore, future studies are needed to investigate the mechanisms by which these drugs interact to inhibit Babesia growth. While the potential role of BPQ in human babesiosis, as well as the use of ELQ-316 alone or in combination with BPQ, is beyond the scope of the current study, it is worth noting that these treatments may warrant further investigation in the context of human infections. This represents an important avenue for future research, especially considering the increase of its global relevance.
This study offers a potential novel approach to address the toxicity and resistance associated with high ID doses. However, further research is required to determine the clearance of this combination from the products of treated animals.
N.M.C.: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Project administration, Writing–original draft, Writing–review and editing, Software. N.F.V.: Supervision, Writing–review and editing, Conceptualization, Data curation, Formal Analysis, Software. P.A.L.: Methodology, Writing–review and editing, Supervision. J.S.D.: Conceptualization, Supervision, Writing–review and editing, Resources, Validation. M.K.R.: Conceptualization, Supervision, Validation, Writing–review and editing. C.E.S.: Supervision, Writing–review and editing. M.W.U.: Supervision, Project administration, Writing–review and editing. C.J.C.: Supervision, Writing–review and editing, Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Validation, Visualization, Writing–original draft. All authors have read and agreed to the published version of the manuscript.
The animal study was approved by the IACUC University of Idaho #2020-42, including bovine and equine bleeding. The study was conducted in accordance with the local legislation and institutional requirements.
Not applicable.
The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers at the time of submission. This had no impact on the peer review process and the final decision.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Enlarge this image.Figure 1. Comparative survival kinetics (median %) of in vitro B. bigemina cultures during 96 h of incubation with different concentrations (nM) of ELQ-316, BPQ, the BPQ + ELQ-316 combination, the ID + ELQ-316 combination, and ID, starting at a 2% parasitemia (PPE), are presented. Error bars represent the standard deviation (n = 3 experiments) for each drug and combinations tested. X axis points represent 0 nM, 25 nM, 75 nM, 150 nM, 300 nM, 600 nM, and 1200 nM in logarithmic scale.
Comparative survival rate (%) of B. bigemina cultures after 96 h in vitro incubation, starting at 2% PPE, in the presence of different concentrations of BPQ, ID and ELQ-316, and their combinations.
| Drug Treatment | BPQ | ID | ELQ-316 | ID + ELQ-316 | BPQ + ELQ-316 |
|---|---|---|---|---|---|
| Median Range (%) | |||||
| 25 | 89.26 (84.30–92.98) | 100 (88–100) | 100 (89.26–100) | 8.80 (6.94–11.9) | 86.78 (79.34–100) |
| 75 | 13.02 (8.68–13.64) a,b | 44.01 (38.43–49.59) b | 0.87 (0.62–0.99) a,b | 0.87 (0.62–0.99) a,c | 0 c |
| 150 | 0.62 (0.37–0.74) a | 6.76 (2.48–11.03) a | 0.65 (0.5–1.12) a | 0 c | 0 c |
| 300 | 1.12 (0.99–1.86) a | 2.48 (1.24–3.72) a | 0.53 (0.37–0.87) a,b | 0 c | 0 c |
a, b, c Drugs with different letters differed (p < 0.05).
In vitro drug potencies (IC50% and IC99%) for B. bigemina at 96 h of incubation.
| Drugs | IC50% (nM) | IC99% (nM) | ||
|---|---|---|---|---|
| Mean | 95% CI | Mean | 95% CI | |
| ID + ELQ-316 | 9.248 | (8.667–9.887) | 65.52 | (61.35–69.81) |
| BPQ + ELQ-316 | 27.59 | N/A | 34.23 | N/A |
| BPQ | 44.66 | (43.56–45.81) | 156.4 | (148.9–164.4) |
| ELQ-316 | 48.10 | (42.76–58.83) | 133 | (102.2–155.6) |
| ID | 61.49 | (59.54–63.46) | 441.4 | (392.3–498) |
N/A, not applicable: CI were not reported for this concentration’s groups because the mathematical models did not fit the data adequately.
Drug concentrations ranges and times at which 0% survival was attained.
| Single Drugs and Combination Treatments | Time Post-Treatment with Drug (h) | Time Post-Treatment Without Drug (h) | ||||||
|---|---|---|---|---|---|---|---|---|
| 48 | 72 | 96 | 24 | 48 | 72 | 96 | 120 | |
| BPQ | - | 1200 | 600 to 1200 | (--------------- 150 to 1200 ------------) | ||||
| BPQ + ELQ-316 | 1200 | 300 to 1200 | (------------------------- 75 to 1200 ----------------------) | |||||
| ELQ-316 | - | 1200 | 600 to 1200 | (--------------- 150 to 1200 ------------) | ||||
| ID + ELQ-316 | - | 600 to 1200 | (--------- 150 to 1200 -------) | (------ 75 to 1200 -----) | ||||
| ID | - | - | 600–1200 | 300–1200 | (----- 150 to 1200 ----) | |||
References
1. Asrar, R.; Farhan, H.R.; Sultan, D.; Ahmad, M.; Hassan, S.; Kalim, F.; Shakoor, A.; Muhammad Taimoor Ihsan, H.; Shahab, A.; Ali, W. et al. Review Article Bovine Babesiosis; Review on Its Global Prevalence and Anticipatory Control for One Health. Cont. Vet. J.; 2022; 2, pp. 42-49.
2. Bock, R.; Jackson, L.; De Vos, A.; Jorgensen, W. Babesiosis of Cattle. Parasitology; 2004; 129, pp. S247-S269. [DOI: https://dx.doi.org/10.1017/S0031182004005190] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15938514]
3. Jacob, S.S.; Sengupta, P.P.; Paramanandham, K.; Suresh, K.P.; Chamuah, J.K.; Rudramurthy, G.R.; Roy, P. Bovine Babesiosis: An Insight into the Global Perspective on the Disease Distribution by Systematic Review and Meta-Analysis. Vet. Parasitol.; 2020; 283, pp. 1-15. [DOI: https://dx.doi.org/10.1016/j.vetpar.2020.109136] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32574977]
4. Pipano, E.; Hadani, A. Control of Bovine Babesiosis. Malaria and Babesiosis; Ristic, M.; Ambroise-Thomas, P.; Kreier, J.P. Springer: Berlin/Heidelberg, Germany, 1984; pp. 263-303.
5. He, L.; Bastos, R.G.; Sun, Y.; Hua, G.; Guan, G.; Zhao, J.; Suarez, C.E. Babesiosis as a Potential Threat for Bovine Production in China. Parasites Vectors; 2021; 14, pp. 1-12. [DOI: https://dx.doi.org/10.1186/s13071-021-04948-3] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34493328]
6. Azhar, M.; Gadahi, J.A.; Bhutto, B.; Tunio, S.; Vistro, W.A.; Tunio, H.; Bhutto, S.; Ram, T. Babesiosis: Current Status and Future Perspectives in Pakistan and Chemotherapy Used in Livestock and Pet Animals. Heliyon; 2023; 9, e17172. [DOI: https://dx.doi.org/10.1016/j.heliyon.2023.e17172] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/37441378]
7. Vial, H.J.; Gorenflot, A. Chemotherapy against Babesiosis. Vet. Parasitol.; 2006; 138, pp. 147-160. [DOI: https://dx.doi.org/10.1016/j.vetpar.2006.01.048] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16504402]
8. Hwang, S.-J.; Yamasaki, M.; Nakamura, K.; Sasaki, N.; Murakami, M.; Kumara, B.; Rajapakshage, W.; Ohta, H.; Maede, Y.; Takiguchi, M. Development and Characterization of a Strain of Babesia gibsoni Resistant to Diminazene Aceturate In Vitro. J. Vet. Med. Sci.; 2010; 72, pp. 765-771. [DOI: https://dx.doi.org/10.1292/jvms.09-0535] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20160418]
9. Tuntasuvan, D.; Jarabrum, W.; Viseshakul, N.; Mohkaew, K.; Borisutsuwan, S.; Theeraphan, A.; Kongkanjana, N. Chemotherapy of Surra in Horses and Mules with Diminazene Aceturate. Vet. Parasitol.; 2003; 110, pp. 227-233. [DOI: https://dx.doi.org/10.1016/S0304-4017(02)00304-7] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12482651]
10. Mosqueda, J.; Olvera-Ramírez, A.; Aguilar-Tipacamú, G.; Cantó, G.J. Current Advances in Detection and Treatment of Babesiosis. Curr. Med. Chem.; 2012; 19, pp. 1504-1518. [DOI: https://dx.doi.org/10.2174/092986712799828355] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22360483]
11. Bailey, G. Buparvaquone Tissue Residue Study; Meat and livestock Australia limited: North Sydney, Australia, 2013; pp. 1-152. Available online: https://www.mla.com.au/research-and-development/reports/2013/buparvaquone-tissue-residue-study/ (accessed on 4 February 2025).
12. Cardillo, N.M.; Lacy, P.A.; Villarino, N.F.; Doggett, J.S.; Riscoe, M.K.; Bastos, R.G.; Laughery, J.M.; Ueti, M.W.; Suarez, C.E. Comparative Efficacy of Buparvaquone and Imidocarb in Inhibiting the in Vitro Growth of Babesia bovis. Front. Pharmacol.; 2024; 15, 1407548. [DOI: https://dx.doi.org/10.3389/fphar.2024.1407548]
13. Carter, P. Assessment of the Efficacy of Buparvaquone for the Treatment of ‘Benign’ Bovine Theileriosis; Meat & Livestock Australia: North Sydney, Australia, 2011; pp. 1-12. Available online: https://www.mla.com.au/research-and-development/reports/2011/assess-the-efficacy-of-buparvaquone-for-the-treatment-of-bovine-theileriosis/ (accessed on 4 February 2025).
14. Checa, R.; Montoya, A.; Ortega, N.; González-Fraga, J.L.; Bartolomé, A.; Gálvez, R.; Marino, V.; Miró, G. Efficacy, Safety and Tolerance of Imidocarb Dipropionate versus Atovaquone or Buparvaquone plus Azithromycin Used to Treat Sick Dogs Naturally Infected with the Babesia microti-like Piroplasm. Parasites Vectors; 2017; 10, pp. 1-14. [DOI: https://dx.doi.org/10.1186/s13071-017-2049-0] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28292316]
15. Goud, S.K.; Vijayakumar, K.; Davis, J.; Tresamol, P.V.; Ravishankar, C.; Devada, K. Efficacy of Different Treatment Regimens against Oriental Theileriosis in Naturally Infected Cattle. Indian J. Vet. Med.; 2021; 40, pp. 14-19.
16. Hudson, A.T.; Randall, A.W.; Fry, M.; Ginger, C.D.; Hill, B.; Latter, V.S.; McHardy, N.; Williams, R.B. Novel Anti-Malarial Hydroxynpahthoquinones with Potent Broad Spectrum Anti-Protozoal Activity. Parasitology; 1985; 90, pp. 45-55. [DOI: https://dx.doi.org/10.1017/S0031182000049003] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/3920634]
17. Kumar, S.; Gupta, A.K.; Pal, Y.; Dwivedi, S.K. In-Vivo Therapeutic Efficacy Trial with Artemisinin Derivative, Buparvaquone and Imidocarb Dipropionate against Babesia equi Infection in Donkeys. J. Vet. Med. Sci.; 2003; 65, pp. 1171-1177. [DOI: https://dx.doi.org/10.1292/jvms.65.1171] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14665744]
18. Muraguri, G.R.; Ngumi, P.N.; Wesonga, D.; Ndungu, S.G.; Wanjohi, J.M.; Bang, K.; Fox, A.; Dunne, J.; McHardy, N. Clinical Efficacy and Plasma Concentrations of Two Formulations of Buparvaquone in Cattle Infected with East Coast Fever (Theileria parva Infection). Res. Vet. Sci.; 2006; 81, pp. 119-126. [DOI: https://dx.doi.org/10.1016/j.rvsc.2005.09.012] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16289157]
19. Wilkie, G.M.; Kirvar, E.; Thomas, E.M.; Sparagano, O.; Brown, C.G.D. Stage-Specific Activity in Vitro on the Theileria Infection Process of Serum from Calves Treated Prophylactically with Buparvaquone. Vet. Parasitol.; 1998; 80, pp. 127-136. [DOI: https://dx.doi.org/10.1016/S0304-4017(98)00204-0] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9870365]
20. Nugraha, A.B.; Tuvshintulga, B.; Guswanto, A.; Tayebwa, D.S.; Rizk, M.A.; Gantuya, S.; El-Saber Batiha, G.; Beshbishy, A.M.; Sivakumar, T.; Yokoyama, N. et al. Screening the Medicines for Malaria Venture Pathogen Box against Piroplasm Parasites. Int. J. Parasitol. Drugs Drug Resist.; 2019; 10, pp. 84-90. [DOI: https://dx.doi.org/10.1016/j.ijpddr.2019.06.004]
21. Müller, J.; Aguado-Martinez, A.; Manser, V.; Balmer, V.; Winzer, P.; Ritler, D.; Hostettler, I.; Solís, D.A.; Ortega-Mora, L.; Hemphill, A. Buparvaquone Is Active against Neospora caninum in Vitro and in Experimentally Infected Mice. Int. J. Parasitol. Drugs Drug Resist.; 2015; 5, pp. 16-25. [DOI: https://dx.doi.org/10.1016/j.ijpddr.2015.02.001]
22. Fray, M.; Pudney, M. Site of Action of the Antimalarial Hydroxynaphthoquinone,2-[Trans-4-(40chlorophenyl)Cyclohexyl]-3-Hydroxy-1,4,-Naphthoquinone (566c80). Biochem. Pharmacol.; 1992; 40, pp. 914-919. [DOI: https://dx.doi.org/10.1016/0006-2952(92)90213-3]
23. Mhadhbi, M.; Chaouch, M.; Ajroud, K.; Darghouth, M.A.; BenAbderrazak, S. Sequence Polymorphism of Cytochrome b Gene in Theileria annulata Tunisian Isolates and Its Association with Buparvaquone Treatment Failure. PLoS ONE; 2015; 10, e0129678. [DOI: https://dx.doi.org/10.1371/journal.pone.0129678]
24. Sharifiyazdi, H.; Namazi, F.; Oryan, A.; Shahriari, R.; Razavi, M. Point Mutations in the Theileria annulata Cytochrome b Gene Is Associated with Buparvaquone Treatment Failure. Vet. Parasitol.; 2012; 187, pp. 431-435. [DOI: https://dx.doi.org/10.1016/j.vetpar.2012.01.016]
25. McConnell, E.V.; Bruzual, I.; Pou, S.; Winter, R.; Dodean, R.A.; Smilkstein, M.J.; Krollenbrock, A.; Nilsen, A.; Zakharov, L.N.; Riscoe, M.K. et al. Targeted Structure-Activity Analysis of Endochin-like Quinolones Reveals Potent Qi and Qo Site Inhibitors of Toxoplasma gondii and Plasmodium falciparum Cytochrome Bc1 and Identifies ELQ-400 as a Remarkably Effective Compound against Acute Experimental Toxoplasmosis. ACS Infect. Dis.; 2018; 4, pp. 1574-1584. [DOI: https://dx.doi.org/10.1021/ACSINFECDIS.8B00133] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30117728]
26. Lawres, L.A.; Garg, A.; Kumar, V.; Bruzual, I.; Forquer, I.P.; Renard, I.; Virji, A.Z.; Boulard, P.; Rodriguez, E.X.; Allen, A.J. et al. Radical Cure of Experimental Babesiosis in Immunodeficient Mice Using a Combination of an Endochin-like Quinolone and Atovaquone. J. Exp. Med.; 2016; 213, pp. 1307-1318. [DOI: https://dx.doi.org/10.1084/jem.20151519]
27. Pritchard, J.R.; Bruno, P.M.; Gilbert, L.A.; Capron, K.L.; Lauffenburger, D.A.; Hemann, M.T. Defining Principles of Combination Drug Mechanisms of Action. Proc. Natl. Acad. Sci. USA; 2012; 110, pp. E170-E179. [DOI: https://dx.doi.org/10.1073/pnas.1210419110]
28. Silva, M.G.; Bastos, R.G.; Stone Doggett, J.; Riscoe, M.K.; Pou, S.; Winter, R.; Dodean, R.A.; Nilsen, A.; Suarez, C.E. Endochin-like Quinolone-300 and ELQ-316 Inhibit Babesia bovis, B. Bigemina, B. Caballi and Theileria Equi. Parasites Vectors; 2020; 13, pp. 1-11. [DOI: https://dx.doi.org/10.1186/s13071-020-04487-3]
29. Eberhard, N.; Balmer, V.; Müller, J.; Müller, N.; Winter, R.; Pou, S.; Nilsen, A.; Riscoe, M.; Francisco, S.; Leitao, A. et al. Activities of Endochin-Like Quinolones Against In Vitro Cultured Besnoitia besnoiti Tachyzoites. Front. Vet. Sci.; 2020; 7, 96. [DOI: https://dx.doi.org/10.3389/fvets.2020.00096] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32161765]
30. Cardillo, N.M.; Villarino, N.F.; Lacy, P.A.; Riscoe, M.K.; Doggett, J.S.; Ueti, M.W.; Chung, C.J.; Suarez, C.E. The Combination of Buparvaquone and ELQ316 Exhibit a Stronger Effect than ELQ316 and Imidocarb Against Babesia bovis In Vitro. Pharmaceutics; 2024; 16, 1402. [DOI: https://dx.doi.org/10.3390/pharmaceutics16111402]
31. Rizk, M.A.; El-Sayed, S.A.E.-S.; Igarashi, I. Diminazene Aceturate and Imidocarb Dipropionate-Based Combination Therapy for Babesiosis—A New Paradigm. Ticks Tick-Borne Dis.; 2023; 14, 102145. [DOI: https://dx.doi.org/10.1016/j.ttbdis.2023.102145] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/37011497]
32. Todorovic, R.A.; Viscaino, O.G.; Gonzalez, E.F.; Adams, L.G. Chemoprophylaxis (Imidocarb) against Babesia bigemina and Babesia argentina Infections. Am. J. Vet. Res.; 1973; 34, pp. 1153-1161. [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/4747036]
33. Silva, M.G.; Villarino, N.F.; Knowles, D.P.; Suarez, C.E. Assessment of Draxxin® (Tulathromycin) as an Inhibitor of in Vitro Growth of Babesia bovis, Babesia bigemina and Theileria equi. Int. J. Parasitol. Drugs Drug Resist.; 2018; 8, pp. 265-270. [DOI: https://dx.doi.org/10.1016/j.ijpddr.2018.04.004]
34. Mazuz, M.L.; Golenser, J.; Fish, L.; Haynes, R.K.; Wollkomirsky, R.; Leibovich, B.; Shkap, V. Artemisone Inhibits in Vitro and in Vivo Propagation of Babesia bovis and B. bigemina Parasites. Exp. Parasitol.; 2013; 135, pp. 690-694. [DOI: https://dx.doi.org/10.1016/j.exppara.2013.10.006] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24184077]
35. Winter, R.; Kelly, J.X.; Smilkstein, M.J.; Hinrichs, D.; Koop, D.R.; Riscoe, M.K. Optimization of Endochin-like Quinolones for Antimalarial Activity. Exp. Parasitol.; 2011; 127, pp. 545-551. [DOI: https://dx.doi.org/10.1016/j.exppara.2010.10.016]
36. Rizk, M.A.; El-Sayed, S.A.E.S.; El-Khodery, S.; Yokoyama, N.; Igarashi, I. Discovering the in Vitro Potent Inhibitors against Babesia and Theileria Parasites by Repurposing the Malaria Box: A Review. Vet. Parasitol.; 2019; 274, 108895. [DOI: https://dx.doi.org/10.1016/j.vetpar.2019.07.003] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31494399]
37. Rizk, M.A.; El-Sayed, S.A.E.S.; Nassif, M.; Mosqueda, J.; Xuan, X.; Igarashi, I. Assay Methods for in Vitro and in Vivo Anti-Babesia Drug Efficacy Testing: Current Progress, Outlook, and Challenges. Vet. Parasitol.; 2020; 279, 109013. [DOI: https://dx.doi.org/10.1016/j.vetpar.2019.109013]
38. Rizk, M.A.; El-Sayed, S.A.E.S.; AbouLaila, M.; Tuvshintulga, B.; Yokoyama, N.; Igarashi, I. Large-Scale Drug Screening against Babesia divergens Parasite Using a Fluorescence-Based High-Throughput Screening Assay. Vet. Parasitol.; 2016; 227, pp. 93-97. [DOI: https://dx.doi.org/10.1016/j.vetpar.2016.07.032] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27523944]
39. Rizk, M.A.; El-Sayed, S.A.E.-S.; Terkawi, M.A.; Youssef, M.A.; El Said, E.S.E.S.; Elsayed, G.; El-Khodery, S.; El-Ashker, M.; Elsify, A.; Omar, M. et al. Optimization of a Fluorescence-Based Assay for Large-Scale Drug Screening against Babesia and Theileria Parasites. PLoS ONE; 2015; 10, e0125276. [DOI: https://dx.doi.org/10.1371/journal.pone.0125276] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25915529]
40. Mehlhorn, H. Babesiacidal Drugs. Encyclopedia of Parasitology; Springer: Berlin/Heidelberg, Germany, 2016; pp. 1-11.
41. Nilsen, A.; Miley, G.P.; Forquer, I.P.; Mather, M.W.; Katneni, K.; Li, Y.; Pou, S.; Pershing, A.M.; Stickles, A.M.; Ryan, E. et al. Discovery, Synthesis, and Optimization of Antimalarial 4(1H)-Quinolone-3-Diarylethers. J. Med. Chem.; 2014; 57, 3818. [DOI: https://dx.doi.org/10.1021/jm500147k]
42. Levy, M.G.; Ristic, M. Babesia bovis: Continuous Cultivation in a Microaerophilous Stationary Phase Culture. Science; 1980; 207, pp. 1218-1220. [DOI: https://dx.doi.org/10.1126/science.7355284]
43. Bennett, T.N.; Paguio, M.; Gligorijevic, B.; Seudieu, C.; Kosar, A.D.; Davidson, E.; Roepe, P.D. Novel, Rapid, and Inexpensive Cell-Based Quantification of Antimalarial Drug Efficacy. Antimicrob. Agents Chemother.; 2004; 48, 1807. [DOI: https://dx.doi.org/10.1128/AAC.48.5.1807-1810.2004]
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
; Suarez, Carlos E 6 ; Ueti, Massaro W 1
; Chung, Chungwon J 1
1 Animal Disease Research Unit, USDA-ARS, 3003 ADBF, WSU, Pullman, WA 99163, USA;
2 Program in Individualized Medicine, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, WA 99164, USA;
3 Animal Disease Research Unit, USDA-ARS, 3003 ADBF, WSU, Pullman, WA 99163, USA;
4 VA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, OR 97239, USA;
5 VA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, OR 97239, USA;
6 Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, WA 99164, USA